Real-time enrollment status for this locally advanced or metastatic her2-expressing cancers clinical trial
Current Status
Recruiting
Checked: September 1, 2026 at 12:47 AM UTC
| NCT Number | NCT05356741 |
| Recruiting Status | Recruiting |
| Condition | Locally Advanced or Metastatic HER2-Expressing Cancers |
| Phase | PHASE1 |
| Target Enrollment | 645 participants |
| Active Locations | 1 sites in the US |
| Sponsor | Vir Biotechnology, Inc. |
| Last Updated on CT.gov | August 19, 2026 (1 week ago) |
As of September 1, 2026: Clinical trial NCT05356741 is currently recruiting participants. This phase1 study for locally advanced or metastatic her2-expressing cancers is actively seeking new participants at 1 location across the United States. The study is sponsored by Vir Biotechnology, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT05356741 is actively recruiting participants as of September 1, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05356741 was last updated 1 week ago (August 19, 2026). HelloStudys verifies this status automatically.